Imaging somatostatin receptors in nasopharyngeal cancer and related EBV cancers
Somatostatin Receptor Imaging in Nasopharyngeal Cancer, Epstein-Barr Virus (EBV) Related Cancers and Other Rare Tumors
This study is testing if patients with advanced nasopharyngeal cancer and other related cancers have a lot of somatostatin receptors, which could help find better treatment options for them.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | National Cancer Centre, Singapore Academic / other |
| Locations | 1 site (Singapore) |
| Trial ID | NCT05581550 on ClinicalTrials.gov |
What this trial studies
This study investigates the presence and density of somatostatin receptors in patients with locally advanced, metastatic, or recurrent nasopharyngeal cancer (NPC) and other Epstein-Barr virus (EBV) related cancers. It aims to assess how many NPC patients exhibit high somatostatin receptor density, which could inform future targeted therapeutic approaches. The study utilizes FDG-PET and Ga-68 DOTATATE imaging techniques to gather data on receptor avidity. By identifying potential candidates for somatostatin-targeted therapies, the research seeks to enhance treatment options for these patients.
Who should consider this trial
Good fit: Ideal candidates include adults over 21 years old with locally advanced, metastatic, or recurrent nasopharyngeal cancer undergoing FDG PET imaging.
Not a fit: Patients under 21 years of age or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved targeted therapies for patients with nasopharyngeal cancer and EBV-related cancers.
How similar studies have performed: While this approach is relatively novel, previous studies have explored somatostatin receptor imaging in other cancers, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations * Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging * Histologically confirmed NPC * Above 21 years of age Exclusion Criteria: * Patients below 21 years of age * Pregnant and breast feeding ladies
Where this trial is running
Singapore
- National Cancer Centre Singapore — Singapore, Singapore (Recruiting)
Study contacts
- Principal investigator: Wen Long Nei, MD — National Cancer Centre, Singapore
- Study coordinator: Wen Long Nei, MD
- Email: nei.wen.long@singhealth.com.sg
- Phone: +65 6436 8000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.